TY - JOUR
T1 - Inducing a mode of NK-resistance to suppression by stress and surgery
T2 - A potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis
AU - Rosenne, Ella
AU - Shakhar, Guy
AU - Melamed, Rivka
AU - Schwartz, Yossi
AU - Erdreich-Epstein, Anat
AU - Ben-Eliyahu, Shamgar
N1 - Funding Information:
This study was supported by NIH/NCI CA73056 grant (S.B.-E.) and by a grant from the Israel Science Foundation (S.B.-E.).
PY - 2007/5
Y1 - 2007/5
N2 - Perioperative suppression of NK activity has been suggested to compromise host resistance to tumor progression. Here, we sought to develop a clinically applicable preoperative regimen to prevent immunosuppression and promotion of metastasis by stress or surgery. The synthetic ds-RNA, poly I-C, was used in vivo in F344 rats, based on its alleged in vitro ability to protect immunocytes from suppression by cAMP elevating agents. Different regimens of poly I-C were studied in controls and in rats subjected to a pharmacological stressor, swim stress, or surgical stress. Resistance to lung experimental metastasis of the syngeneic non-immunogenic MADB106 mammary adenocarcinoma was assessed. Numbers of circulating and marginating-pulmonary NK cells and their cytotoxicity against the MADB106 and YAC-1 target lines were also studied. Our findings established a regimen of repeated low-dose poly I-C administration with minimal side effects (0.2 mg/kg i.p. 5, 3, and 1 day before tumor inoculation). This regimen, while hardly affecting resistance levels in non-stressed animals, prevented all stressors from promoting metastases. These beneficial effects occurred in the presence of a primary tumor and in both sexes. Poly I-C increased the numbers of NK cells, and, on a per NK cell basis, while not increasing cytotoxicity, profoundly protected marginating-pulmonary NK cells from suppression by surgery. This study suggests a non-toxic clinically translatable prophylactic use of poly I-C to target the critical perioperative period. By increasing the number of marginating-pulmonary NK cells, and by transforming them into a mode of resistance to immunosuppression, this approach may reduce postoperative metastasis in cancer patients.
AB - Perioperative suppression of NK activity has been suggested to compromise host resistance to tumor progression. Here, we sought to develop a clinically applicable preoperative regimen to prevent immunosuppression and promotion of metastasis by stress or surgery. The synthetic ds-RNA, poly I-C, was used in vivo in F344 rats, based on its alleged in vitro ability to protect immunocytes from suppression by cAMP elevating agents. Different regimens of poly I-C were studied in controls and in rats subjected to a pharmacological stressor, swim stress, or surgical stress. Resistance to lung experimental metastasis of the syngeneic non-immunogenic MADB106 mammary adenocarcinoma was assessed. Numbers of circulating and marginating-pulmonary NK cells and their cytotoxicity against the MADB106 and YAC-1 target lines were also studied. Our findings established a regimen of repeated low-dose poly I-C administration with minimal side effects (0.2 mg/kg i.p. 5, 3, and 1 day before tumor inoculation). This regimen, while hardly affecting resistance levels in non-stressed animals, prevented all stressors from promoting metastases. These beneficial effects occurred in the presence of a primary tumor and in both sexes. Poly I-C increased the numbers of NK cells, and, on a per NK cell basis, while not increasing cytotoxicity, profoundly protected marginating-pulmonary NK cells from suppression by surgery. This study suggests a non-toxic clinically translatable prophylactic use of poly I-C to target the critical perioperative period. By increasing the number of marginating-pulmonary NK cells, and by transforming them into a mode of resistance to immunosuppression, this approach may reduce postoperative metastasis in cancer patients.
KW - Immunity
KW - Metastasis
KW - Natural killer
KW - Poly I-C
KW - Stress
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=34047095585&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2006.12.002
DO - 10.1016/j.bbi.2006.12.002
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:34047095585
SN - 0889-1591
VL - 21
SP - 395
EP - 408
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
IS - 4
ER -